Ciba-Geigy Canada Ltd v Apotex Inc

mTOR Inhibitors Market Poised for Steady Growth - Expected to Reach $7.11 Billion in 2023

Retrieved on: 
Monday, September 18, 2023
GSK, Laboratory, Ciba-Geigy Canada Ltd v Apotex Inc, AbbVie, Exelixis, Agriculture, COVID-19, Pfizer, Merck & Co., Alkem Laboratories, AstraZeneca, GSK plc, Compound annual growth rate, Endo International, Bristol Myers Squibb, Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective, Microsoft Excel, Eli Lilly and Company, Merck, Country, Novartis, Pharmaceutical industry, Retail

DUBLIN, Sept. 18, 2023 /PRNewswire/ -- The "mTOR Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 18, 2023 /PRNewswire/ -- The "mTOR Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The global mTOR inhibitors market is on a steady growth path, with an expected increase from $6.70 billion in 2022 to $7.11 billion in 2023, reflecting a Compound Annual Growth Rate (CAGR) of 6.05%.
  • This growth trajectory is set to continue, reaching $8.76 billion by 2027 at a CAGR of 5.38%.
  • Inflation Analysis: Measure the influence of high global inflation on market growth.

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Maintenance, Ciba-Geigy Canada Ltd v Apotex Inc, Nephrology, Amgen, Policy, Myasthenia gravis, Ophthalmology, Immunomodulation, NMOSD, Patient, IgG4-related disease, Physician, Rheumatology, CAS, Growth, American Association of Clinical Endocrinologists, Neuromyelitis optica spectrum disorder, Pharmaceutical industry, TED

Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales.

Key Points: 
  • Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales.
  • Second-quarter and year-to-date 2022 UPLIZNA net sales included $8.6 million and $13.8 million, respectively, in international net sales.
  • The second-quarter results were driven by execution across all phases of the patient journey – demand generation, stakeholder education and adherence to treatment.
  • In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, the Company will not be hosting a conference call to discuss its financial results.

North America Dominates the Global Gabapentin Market with Developed Healthcare System and High Adoption Rates - ResearchAndMarkets.com

Retrieved on: 
Monday, August 7, 2023
Health, Pharmaceutical, Epilepsy, Laboratory, Ciba-Geigy Canada Ltd v Apotex Inc, Gabapentin, Sun Pharma, Policy, Pfizer, USD, Market, Incidence, Hospital, Application, Risk, Neuropathic pain, Aurobindo Pharma, Drug, Growth, Generic, Pharmaceutical industry, Generic drug, Capsule

The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.35% from 2023 to 2030.

Key Points: 
  • The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.35% from 2023 to 2030.
  • The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.
  • Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.
  • North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin.

Piramal Pharma Limited Announces Consolidated Results for Q1FY24

Retrieved on: 
Thursday, August 3, 2023
Ciba-Geigy Canada Ltd v Apotex Inc, API, ICH, Prestige Consumer Healthcare, INR, EBITDA, CDMO, Yoy, ADC, ESG, Growth, CHG, Fine chemical, Sevoflurane

81, Record Date of August 2, 2023 and Entitlement Ratio of 5:46

Key Points: 
  • 81, Record Date of August 2, 2023 and Entitlement Ratio of 5:46
    Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We had a positive start to the new financial year with healthy revenue growth and improvement in our EBITDA margins.
  • Our CDMO business is also witnessing continued order inflows, especially for our differentiated offerings and innovation related work.
  • Our Inhalation Anesthesia portfolio is seeing a healthy demand and our India Consumer Healthcare business is delivering good growth driven by power brands.
  • We believe in the growth potential of our business and are accordingly executing on our strategic priorities to create shareholder value.

Piramal Pharma Limited Announces Consolidated Results for Q1FY24

Retrieved on: 
Thursday, August 3, 2023
Ciba-Geigy Canada Ltd v Apotex Inc, API, ICH, Prestige Consumer Healthcare, INR, EBITDA, CDMO, Yoy, ADC, ESG, Growth, CHG, Fine chemical, Sevoflurane

81, Record Date of August 2, 2023 and Entitlement Ratio of 5:46

Key Points: 
  • 81, Record Date of August 2, 2023 and Entitlement Ratio of 5:46
    Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We had a positive start to the new financial year with healthy revenue growth and improvement in our EBITDA margins.
  • Our CDMO business is also witnessing continued order inflows, especially for our differentiated offerings and innovation related work.
  • Our Inhalation Anesthesia portfolio is seeing a healthy demand and our India Consumer Healthcare business is delivering good growth driven by power brands.
  • We believe in the growth potential of our business and are accordingly executing on our strategic priorities to create shareholder value.

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Ciba-Geigy Canada Ltd v Apotex Inc, Nephrology, Amgen, Immunomodulation, Methotrexate, Patient, Physician, Rheumatology, CAS, Growth, Pharmaceutical industry, TED

First-quarter 2023 UPLIZNA net sales included $6.6 million in international net sales related primarily to revenue and milestone payments from the Company’s international partners.

Key Points: 
  • First-quarter 2023 UPLIZNA net sales included $6.6 million in international net sales related primarily to revenue and milestone payments from the Company’s international partners.
  • TEPEZZA: TEPEZZA net sales in the first quarter were $405 million, representing an 18 percent sequential decline compared to the fourth quarter of 2022.
  • Net sales were impacted by seasonality, which the Company typically sees with its infused medicines in the first quarter each year.
  • UPLIZNA: UPLIZNA first-quarter 2023 net sales were $53.8 million, representing a year-over-year increase of 77%, driven by continued strong execution.

Apotex Receives FDA's Drug Shortage Assistance Award

Retrieved on: 
Wednesday, April 19, 2023
Tablet, Health Canada, Varenicline, ANDA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Food, Ciba-Geigy Canada Ltd v Apotex Inc, Public, Pharmaceutical industry, Generic drug, Apotex

TORONTO, April 19, 2023 /PRNewswire/ - Apotex Inc. is pleased to announce that it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA) in recognition of the company's substantial efforts to resolve a shortage of varenicline tablets.

Key Points: 
  • TORONTO, April 19, 2023 /PRNewswire/ - Apotex Inc. is pleased to announce that it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA) in recognition of the company's substantial efforts to resolve a shortage of varenicline tablets.
  • The award also recognizes the submission and ultimate approval of an abbreviated new drug application (ANDA) for varenicline tablets in the U.S. market.
  • "We're proud to receive this important award from the FDA, and to be recognized for our commitment to public health" said Allan Oberman, President and Chief Executive Officer, Apotex.
  • Working with drug companies and manufacturers like Apotex, the FDA helped prevent 317 drug shortages in 2021.

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Wednesday, March 1, 2023
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Amgen, Laboratory, COVID-19, Ciba-Geigy Canada Ltd v Apotex Inc, Pharmaceutical industry, Generic drug

Fourth-quarter and full-year 2022 UPLIZNA net sales included $1.3 million and $18.3 million, respectively, in international net sales, related primarily to revenue and milestone payments from the Company’s international partners.

Key Points: 
  • Fourth-quarter and full-year 2022 UPLIZNA net sales included $1.3 million and $18.3 million, respectively, in international net sales, related primarily to revenue and milestone payments from the Company’s international partners.
  • On May 6, 2022, Apotex Inc. initiated an at-risk launch of generic PENNSAID 2% in the United States.
  • On Aug. 4, 2021, Alkem Laboratories, Inc. initiated an at-risk launch of generic DUEXIS in the United States.
  • In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, Horizon will not be hosting a conference call to discuss its financial results.

Clean Air Metals Files Q3/22 Interim Financial Statements

Retrieved on: 
Wednesday, December 28, 2022
Geology, Conversation, City, SEDAR, Lac, First Nations, Mining, North American Palladium, Platinum, Impala Platinum, Thunder Bay North Stars, National instrument, Panorama, Metal, PEA, TSX Venture Exchange, Fort William First Nation, Palladium, IRR, Exploration, Copper, Agreement, Area studies, Legislation, Sale, Fortification, Maintenance, Ciba-Geigy Canada Ltd v Apotex Inc, Norilsk

Clean Air Metals Inc. and its wholly-owned subsidiary Panoramic PGMs (Canada) Ltd. acknowledge that the Thunder Bay North Critical Minerals Project is on the traditional territories of the Fort William First Nation, Red Rock Indian Band and Biinjitiwabik Zaaging Anishinabek.

Key Points: 
  • Clean Air Metals Inc. and its wholly-owned subsidiary Panoramic PGMs (Canada) Ltd. acknowledge that the Thunder Bay North Critical Minerals Project is on the traditional territories of the Fort William First Nation, Red Rock Indian Band and Biinjitiwabik Zaaging Anishinabek.
  • About Clean Air Metals Inc.
    Clean Air Metals' flagship asset is the 100% owned, high grade Thunder Bay North Project, a platinum, palladium, copper, nickel project located near the City of Thunder Bay, Ontario and the Lac des Iles Mine owned by Impala Platinum.
  • Abraham Drost, Chief Executive Officer of Clean Air Metals Inc.
  • Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Specialty Generics Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Wednesday, December 21, 2022
Cream, Organization, Human, Research report, Tretinoin, Patient, Benzoyl peroxide, Endo International, Rheumatoid arthritis, Gross domestic product, Skin, Cancer, Degenerative disease, Growth, Ciba-Geigy Canada Ltd v Apotex Inc, COVID-19, Multiple sclerosis, Acne, Chronic condition, Pfizer, BPO, Viatris, Prevalence, ZNZ, Infection, Pharmacy, Critical care, Conditional sentence, American Action Network, Geography, Acquisition, Mallinckrodt, Renewable energy, Pharmaceutical industry, Hospital, Poultry, Fine chemical, Novartis

The specialty generics market is expected to grow to $116.63 billion in 2026 at a CAGR of 11.63%.

Key Points: 
  • The specialty generics market is expected to grow to $116.63 billion in 2026 at a CAGR of 11.63%.
  • The regions covered in the specialty generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The specialty generics market research report is one of a series of new reports that provides specialty generics market statistics, including specialty generics industry global market size, regional shares, competitors with a specialty generics market share, detailed specialty generics market segments, market trends and opportunities, and any further data you may need to thrive in the specialty generics industry.
  • This specialty generics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.